Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) shares traded up 2.8% on Monday . The company traded as high as $3.75 and last traded at $3.71, with a volume of 203,044 shares trading hands. The stock had previously closed at $3.61.

Several analysts recently issued reports on the company. Chardan Capital decreased their target price on Aralez Pharmaceuticals from $15.50 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, March 16th. Dundee Securities decreased their target price on Aralez Pharmaceuticals from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, March 16th.

The firm’s market cap is $237.51 million. The stock’s 50 day moving average is $3.65 and its 200 day moving average is $4.68.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.48. The firm earned $8.10 million during the quarter, compared to analyst estimates of $9.70 million. The company’s revenue for the quarter was up 84.1% compared to the same quarter last year. On average, analysts forecast that Aralez Pharmaceuticals Inc. will post ($1.00) earnings per share for the current fiscal year.

In other news, CFO Scott J. Charles acquired 50,000 shares of the business’s stock in a transaction dated Thursday, May 12th. The shares were acquired at an average cost of $3.49 per share, with a total value of $174,500.00. Following the completion of the acquisition, the chief financial officer now owns 213,368 shares of the company’s stock, valued at $744,654.32. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Andrew I. Koven acquired 71,500 shares of the business’s stock in a transaction dated Thursday, May 12th. The stock was purchased at an average cost of $3.49 per share, for a total transaction of $249,535.00. Following the completion of the acquisition, the insider now directly owns 1,610,306 shares of the company’s stock, valued at approximately $5,619,967.94. The disclosure for this purchase can be found here.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.